Short-term efficacy and safety of neoadjuvant pyrotinib plus taxanes for early HER2-positive breast cancer: a single-arm exploratory phase II trial.

Fiche publication

Date publication

mars 2024

Journal

Gland surgery

Auteurs

Membres identifiés du Cancéropôle Est :
Pr PIVOT Xavier

Tous les auteurs :
Ye G, Chen P, Liu X, He T, Pivot X, Pan R, Zhou D, Zhu L, Zhang K, Li W, Yang S, Lin J, Cai G, Huang H

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/38601287

Résumé

The effectiveness and safety of pyrotinib have been substantiated in human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer (BC). However, the role of pyrotinib as a single HER2 blockade in neoadjuvant setting among BC patients has not been studied. The objective of this study was to evaluate the efficacy and tolerability of pyrotinib plus taxanes as a novel neoadjuvant regimen in patients with HER2-positive early or locally advanced BC.